Mobile

A study comparing the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 versus commercially available rituximab in treating patients with low tumor burden follicular lymphoma in the...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-000132-41

A study comparing the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 versus commercially available rituximab in treating patients with low tumor burden follicular lymphoma in the first-line treatment setting

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the efficacy of rituximab-Pfizer to rituximab-EU when administered as a first-line treatment to patients with CD20-positive, low tumor burden follicular lymphoma (LTB-FL). Comparar la eficacia de rituximab-Pfizer con rituximab-UE al administrarlo como tratamiento de primera línea a pacientes con linfoma folicular y baja carga tumoral (LF-BCT) CD20 positivo.

Critère d'inclusion

  • low tumor burden follicular lymphoma,linfoma folicular de baja carga tumoral

Liens